1. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs);Anderson;Oncologist,2009
2. Dermatologic toxicities of targeted anticancer therapies;Balagula;J. Support Oncol.,2010
3. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis;Belum;Invest. New Drugs,2013
4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic diff erentiated thyroid cancer: a randomised, double-blind, phase 3 trial;Brose;Lancet,2014
5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial;Bruix;Lancet Oncol.,2015